What is the recommended dosing regimen and safety counseling for Apretude (cabotegravir) as HIV pre‑exposure prophylaxis in a woman?

Apretude for PrEP in Women

Apretude (cabotegravir long-acting injectable) is highly recommended for HIV pre-exposure prophylaxis in women, administered as 600 mg intramuscular gluteal injections: initial two doses 4 weeks apart, then every 8 weeks thereafter. 112

Dosing Regimen

Initial Dosing

• Oral lead-in is optional (4-5 weeks with cabotegravir 30 mg daily) but recommended only for women with severe atopic histories or those who specifically request it 11
• Do NOT use oral lead-in if the woman has difficulty with daily pill adherence—this defeats the purpose of long-acting therapy 11

Injectable Schedule

• 600 mg (3 mL) intramuscular injection in the gluteal muscle 112
• First two injections: 4 weeks apart
• Maintenance injections: every 8 weeks 11
• Critical: Use only gluteal injections—anterior thigh injections failed to achieve adequate drug levels and had poor tolerability 1

Bridging Coverage

• Overlap first injection with 7 days of oral PrEP (tenofovir-based regimen) to ensure protection while cabotegravir reaches therapeutic levels 11
• Provide 1-month supply of tenofovir-based oral PrEP for emergency bridging if injection appointments are delayed ≥7 days 11

Late Injection Management

• If 8+ weeks late for injection #2 (≥12 weeks from injection #1): restart with two "reloading" doses 4 weeks apart before resuming every-8-week schedule 1
• If 8+ weeks late for injection #3 or beyond (≥16 weeks from previous): same reloading protocol 1

Safety Counseling and Monitoring

Pre-Initiation Requirements

Confirm HIV-negative status using:

• HIV antibody test within 7 days, OR
• Rapid point-of-care test on initiation day 12
• If recent high-risk exposure (<1 month) or acute HIV symptoms present: use FDA-approved test for acute/primary HIV infection 2
• Never initiate if HIV status uncertain—resistance can develop rapidly with monotherapy 2

Ongoing HIV Testing

• Test before every injection (every 8 weeks) 2
• Test upon diagnosis of any sexually transmitted infection 2
• If HIV test suggests possible infection or acute symptoms develop: perform additional confirmatory testing immediately 2

Key Safety Warnings for Women

Injection site reactions are common (occurred in up to 81% of trial participants) but rarely lead to discontinuation 32. Counsel that pain, nodules, and swelling at injection sites are expected and typically resolve.

Long-acting properties create unique risks:

• Cabotegravir remains in the body for up to 12 months or longer after last injection 2
• If HIV is acquired during or after stopping Apretude, resistance to integrase inhibitors can develop 24
• Transition to alternative PrEP within 2 months of final injection if HIV risk continues 1

Pregnancy considerations:

• Apretude is not recommended to initiate during pregnancy due to inadequate safety data 1
• If pregnancy occurs while on Apretude, switch to oral triple-drug ART regimen (dolutegravir + TAF/FTC or TDF/FTC preferred) 1
• Recent case series suggest continuing CAB/RPV with oral supplementation may be feasible, but this is for treatment, not PrEP 5

Hypersensitivity Risk

• Serious reactions including Stevens-Johnson syndrome/toxic epidermal necrolysis reported 2
• Discontinue immediately if hypersensitivity suspected 2
• This is why oral lead-in was used in trials—to identify at-risk individuals before committing to long-acting injections 2

Efficacy Evidence in Women

Apretude demonstrated 79% reduction in HIV acquisition compared to oral TDF/FTC in cisgender women in the HPTN 084 trial 4. The superiority over daily oral PrEP makes it particularly valuable for women who struggle with daily pill adherence 6.

In adolescent girls (HPTN 084-01), Apretude was safe, tolerable, and acceptable, with 93% completing all scheduled injections and 62% reporting they would use it for future HIV prevention 7.

Common Pitfalls to Avoid

1. Don't require oral lead-in for women with adherence challenges—you're selecting against the population most likely to benefit 1
2. Don't use alternative injection sites—only gluteal injections achieve adequate drug levels 1
3. Don't forget the 7-day oral overlap after first injection—protection is not immediate 11
4. Don't miss the reloading protocol for late injections—standard dosing won't achieve therapeutic levels 1
5. Don't continue Apretude if pregnancy confirmed—switch to complete ART regimen 1

Adherence Support

Women, particularly adolescents, may benefit from frequent counseling to support adherence to the every-8-week injection schedule 2. The bimonthly schedule is far more forgiving than daily oral PrEP, but missed appointments still compromise protection due to the long-acting formulation's pharmacokinetics.